Actively Recruiting
Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy
Led by Guizhou Provincial People's Hospital · Updated on 2023-07-18
30
Participants Needed
1
Research Sites
217 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cervical cancer CC is the most common malignant tumor in the female reproductive system, seriously endangering women's health and life, and is one of the leading causes of death for women worldwide.Globally, HPV causes about 85% of cervical cancers and about 60% of oropharyngeal cancers, causing more than 500,000 cancers each year.ctDNA is a potential biomarker because it contains tumor-specific genetic and epigenetic abnormalities that can be used in cancer diagnosis and prognosis prediction.MRD is considered a promising prognostic marker that can be used to identify individuals at increased risk of recurrence and individuals who may benefit from treatment.The expression level of MRD and plasma HPV before and after radiotherapy and chemotherapy for cervical cancer was analyzed by liquid biopsy ctDNA detection technology, which predicted the efficacy of cervical cancer radiotherapy and chemotherapy, which was helpful for monitoring and estimating the risk of disease recurrence after cervical cancer radiotherapy and chemotherapy, and verified the expression of MRD and plasma HPV as the basis for adjuvant chemotherapy after cervical cancer radiotherapy and the basis for optimal chemotherapy time node selection.
CONDITIONS
Official Title
Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years old
- Pathologically confirmed cervical cancer
- Ability to undergo imaging or PET/CT scans and complete all follow-ups
- Measurable lesions before treatment
- Good physical condition with ECOG score 0-1 or KPS score 70-100
- Estimated survival of at least 6 months
- Baseline blood and biochemical tests meeting specific standards (hemoglobin ≥ 80g/L, neutrophil count ≥ 1.5x10^9/L, platelets ≥ 100x10^9/L, ALT and AST ≤ 2.5 times normal upper limit, serum albumin ≥ 30 g/L)
- If patient has syphilis, treatment before study start is required
- No allergy history to rubber products
- Basic normal cardiopulmonary function
You will not qualify if you...
- Allergy to rubber products
- Severe acute infection or uncontrolled chronic infection wounds
- Active chronic hepatitis B, active tuberculosis, syphilis outbreak, or AIDS
- Severe heart diseases such as congestive heart failure, unstable angina, or severe valvular disease
- Neurological or psychiatric disorders that are difficult to control or poor compliance
- Uncontrolled primary brain tumors or central nervous system metastases
- Malignant serous effusion
- History of severe enteritis, cystitis, bleeding, intestinal perforation, or fistulas
- Participation in other clinical trials
- Any other condition deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yong Li
Guiyang, Guizhou, China
Actively Recruiting
Research Team
Y
Yong Li, Chief physician
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here